- Home
- PUMP vs BBNX Comparison
PUMP vs BBNX Comparison
Compare PUMP & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PUMP | BBNX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | 409 |
| Industry | Oilfield Services/Equipment | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2017 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PUMP | BBNX |
|---|---|---|
| Price | $10.29 | $29.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $10.43 | ★ $28.09 |
| AVG Volume (30 Days) | ★ 2.5M | 672.2K |
| Earning Date | 10-29-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,300,037,000.00 | $88,570,000.00 |
| Revenue This Year | N/A | $52.13 |
| Revenue Next Year | $1.59 | $36.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 67.01 |
| 52 Week Low | $4.51 | $8.89 |
| 52 Week High | $11.66 | $32.71 |
Technical Indicators
Market Signals| Indicator | PUMP | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 57.16 |
| Support Level | $10.57 | $28.00 |
| Resistance Level | $11.65 | $31.51 |
| Average True Range (ATR) | 0.57 | 1.88 |
| MACD | -0.02 | -0.29 |
| Stochastic Oscillator | 49.43 | 40.50 |
Price Performance
Historical ComparisonAbout PUMP ProPetro Holding Corp.
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.